The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Anti-TNFα therapy in inflammatory lung diseases
Open accessAbstract
&NA; Increased levels of tumor necrosis factor (TNF) &agr; have been linked to a number of pulmonary inflammatory diseases including asthma, chronic obstructive pulmonary disease (COPD), acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), sarcoidosis, and interstitial pulmonary fibrosis (IPF). TNF&agr; plays multiple roles in disease pathology by inducing an accumulation of inflammatory cells, stimulating the generation of inflammatory mediators, and causing oxidative and nitrosative stress, airway hyperresponsiveness and tissue remodeling. TNF&agr;‐targeting biologics, therefore, present a potentially highly efficacious treatment option. This review summarizes current knowledge on the role of TNF&agr; in pulmonary disease pathologies, with a focus on the therapeutic potential of TNF&agr;‐targeting agents in treating inflammatory lung diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Signalling pathways of the TNF superfamily: a double-edged sword
Aggarwal, B. B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1184 · Cited by 2,793
TNF and ROS crosstalk in inflammation
Blaser, H., Dostert, C., Mak, T. W., & Brenner, D. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.12.002 · Cited by 1,008 · cited 1×
“TNFα is thought to be amajor inducer of oxidative and nitrosative stress in inflammatory cells (Blaser et al., 2016).”
Aggarwal, B. B., Gupta, S. C., & Kim, J. H. (2012) · Blood · doi:10.1182/blood-2011-04-325225 · Cited by 877
Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial
Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1446oc · Cited by 370
TNFα Antagonists for Acute Exacerbations of COPD: A Randomised Double-Blind Controlled Trial
Aaron, S. D., Vandemheen, K. L., Maltais, F., Field, S. K., Sin, D. D., Bourbeau, J., Marciniuk, D. D., FitzGerald, J. M., Nair, P., & Mallick, R. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202432 · Cited by 103 · cited 1×
“Consistent with these findings, clinical trials of monoclonal anti-TNFα antibody in patients with sepsis-induced ALI did not improve survival (Abraham et al., 1995, 1998), whereas p55 TNFR fusion protein treatment of patients with severe septic shock reduced mortality (Abraham et al., 1997).”
Cited by
Role of Macrophages in Acute Lung Injury and Chronic Fibrosis Induced by Pulmonary Toxicants
Laskin, D. L., Malaviya, R., & Laskin, J. D. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfy309 · Cited by 267
Self-citationBiomarkers for Acute Respiratory Distress syndrome and prospects for personalised medicine
Spadaro, S., Park, M., Turrini, C., Tunstall, T., Thwaites, R., Mauri, T., Ragazzi, R., Ruggeri, P., Hansel, T. T., Caramori, G., et al. (2019) · Journal of Inflammation · doi:10.1186/s12950-018-0202-y · Cited by 266
Quijada, H., Bermudez, T., Kempf, C. L., Valera, D. G., Garcia, A. N., Camp, S. M., Song, J. H., Franco, E., Burt, J. K., Sun, B., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02536-2020 · Cited by 88
Metadata
- Authors
- Malaviya, R., Laskin, J. D., & Laskin, D. L.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 180
- Pages
- 90-98
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2658967184
- Cited by
- 235
- References
- 6
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.